vantagebiotrials - Vantage Biotrials

White Papers-FR September 3, 2022 vantagebiotrials Comments: 0

Planning a Positive Outcome for Your Clinical Trial

Planning a Positive Outcome for Your Clinical Trial Publication date: September 2022 / Download PDF Author: Vatche Bartekian Co-Authors: Johanna Garcia, Kaiser Lagman, Marina Ohouo, Sheila Ernest Introduction The drug development process presents many complex steps and requires a keen set of skills, knowledge, and resources to arrive successfully at subsequent stages . Within the various phases of drug development, clinical trials, in particular, require robust, coordinated processes and systems...

archive-events-EN August 22, 2022 vantagebiotrials Comments: 0

CRAC Conference | Health Canada Inspectorate Update | June 8, 2023

Vantage BioTrials will be attending the CRAC Dinner Meeting Event on June 8, 2023 where Health Canada will be presenting the latest on the inspections and trends from 2022. For more information about this conference, please click here....

news-pressroom-EN July 22, 2022 vantagebiotrials Comments: 0

Vantage BioTrials Is Now Using Smartsheet Clinical Trial Management System

July 18, 2022, Montréal, Canada – Vantage BioTrials, a full-service Contract Research Organization (CRO), has on-boarded a robust technology solution to manage its growing demand of early/late phase and medical device clinical trials. Accuracy, flexibility, and speed in obtaining real-time data are crucial. During the last couple of years of the Covid-19 pandemic, Vantage BioTrials remained focused in identifying areas of development that will add value to the overall maintenance, tracking a...

news-pressroom-EN August 22, 2021 vantagebiotrials Comments: 0

Vantage BioTrials Successfully Manages Real-World Effectiveness of Adalimumab in Patients with Moderate-to-Severe Hidradenitis Suppurativa: the 1-Year SOLACE Study

August 30, 2021, Montréal, Canada – Vantage BioTrials, a full service Contract Research Organization (CRO), is proud to have successfully managed, and completed approximately 12 months in advance, a Phase IV observational, multicentre, postmarketing study in adult patients with a clinical diagnosis of moderate-to-severe Hidradenitis suppurativa (HS). The primary objective of this clinical trial was to measure real-world effectiveness of adalimumab in HS and to secondarily observe cli...

White Papers-FR January 3, 2021 vantagebiotrials Comments: 0

CRO SELECTION: How to Find & Select the Right Partner for your Clinical Trial

CRO SELECTION: How to Find & Select the Right Partner for your Clinical Trial Publication date: January 2021 / Download PDF Author: Marc Assaad Introduction As innovation, research and science are exponentially growing in all directions within the healthcare industry, it is only normal that the outsourcing of Clinical Research Organizations (CROs) is also rapidly growing, resulting in a spike in the numbers of such organizations available to the market. The task of finding and filtering thro...

news-pressroom-EN August 22, 2020 vantagebiotrials Comments: 0

COVID-19 Clinical Trial Managed by Vantage BioTrials Receives Green-Light from FDA to Proceed in the United States

August 27, 2020, Montréal, Canada – Vantage BioTrials, a full service Contract Research Organization (CRO), has partnered with its biotech Sponsor, Laurent Pharmaceuticals, to lead all clinical trial management activities of their lead oral drug candidate LAU-7b in a multicentric Phase 2 placebo-controlled clinical trial (RESOLUTION) in patients with COVID-19. We are pleased to join Laurent Pharmaceuticals in announcing that approval has been received from the Food and Drug Administration (F...

news-pressroom-EN February 19, 2020 vantagebiotrials Comments: 0

Vantage BioTrials Successfully Completes Clinical Trial Enrollment 12 Months Ahead of Schedule

Post Marketing Observational Epidemiological Study: Assessing Drug’s Real-life Effectiveness and Impact on Rare Dermatological Indication Burden of Illness and Health Care Resources Utilization MONTREAL, February 19, 2020 – Vantage BioTrials was appointed by its Pharmaceutical Sponsor to manage their Phase IV Post Market Observational Epidemiological clinical trial in a rare dermatological disease. The set enrollment expectation by the Pharmaceutical Sponsor was to recruit 145 patients a...

news-pressroom-EN February 22, 2019 vantagebiotrials Comments: 0

Canada’s Most Trusted Clinical Research and Trial Management Organization in 2018

MONTREAL, February 7, 2019 – Vantage BioTrials is a full-service Contract Research Organization (CRO) based in Canada that provides Phase I-IV clinical trial management services to pharmaceutical, biotechnology & medical device companies. Since inception, Vantage BioTrials has been providing Phase I-IV clinical trial management services to pharmaceutical, biotechnology & medical device companies, along with operational capabilities across North America, Latin America, and Europe. Van...

news-pressroom-EN January 7, 2019 vantagebiotrials Comments: 0

Vantage BioTrials Passes Health Canada Inspection

January 7, 2019, Montreal, Canada – Earlier this year, Vantage BioTrials (VBT) took a very important step forward by volunteering to take part in the first of its kind Health Canada pilot inspection program. The program focused on VBT’s internal processes, procedures & protocol specific studies. “Through our dedication & transparency for adhering to quality principles, we continue to add tangible credibility towards achieving operational excellence for our clients, pati...

news-pressroom-EN August 22, 2018 vantagebiotrials Comments: 0

Vantage BioTrials awarded “Biotechnology CRO of the Year 2018 – Quebec”

August 20, 2018, Montreal, Canada – Vantage BioTrials has been named the “Biotechnology CRO of the Year 2018 – Quebec” by GHP Magazine. Vantage BioTrials is a full-service CRO based in Canada that provides Phase I-IV clinical trial management services to pharmaceutical, biotechnology and medical device companies and with operational capabilities across North America, Latin America, and Europe. Viken Bartekian, Vice-President, Corporate Development, explains more. Vantage BioTria...